Press release
Creative Diagnostics Introduces New Nipah Virus Antigens and Antibodies
As a global leading supplier of raw materials, antibodies, and reagents for bio-technology industry, Creative Diagnostics recently launches a series of NiV recombinant antigen and antibody pairs. All of these new products are produced using standardized production processes to ensure the highest quality. Tests developed using these reagents can assist researchers in routine diagnostics and NiV vaccine development.Nipah virus (NiV) was initially isolated and identified in 1999 during an outbreak of encephalitis and respiratory disease among pig farmers and close contacts of pigs in Malaysia and Singapore. It belongs to the newly created genus Henipavirus and is closely related to Hendra virus and Cedar virus. The Henipavirus family is pleomorphic, which means they come in a variety of shapes, typically 40 to 600 nm in diameter. The core of the virion contains a linear ribonucleoprotein (RNP) composed of negative-sense single-stranded RNA.
NiV is a highly pathogenic zoonotic virus carried by fruit bats (mainly Pteropus spp) and transmitted from bats to humans. Severe encephalitis and respiratory illnesses caused by NiV infection have occurred almost annually in Bangladesh and India since 2001. However, there are currently no licensed treatments and vaccines for NiV infection in humans.
NiV has two membrane-anchored glycoproteins involved in virion cell attachment and subsequent host cell entry, the attachment protein (G) and the fusion protein (F), which are ideal targets for neutralizing antibodies. Various immunization strategies have been developed to prevent NiV infection by utilizing G and/or F glycoprotein antigens, including viral vectors, subunit vaccines, virus-like particles (VLPs) and mRNA vaccines.
NiV causes acute encephalitis and high mortality (40-75%). Therefore, effective NiV vaccines and therapeutics are urgently needed. Laboratory detection of NiV can be performed using real-time polymerase chain reaction (RT-PCR) and enzyme-linked immunosorbent assay (ELISA). Creative Diagnostics now expands its portfolio and releases a series of NiV recombinant antigen and antibody pairs for research use.
Antibodies products such as Anti-Nipah Virus G Protein monoclonal antibody (DMAB-A002), and Magic™ Anti-NIV gF Monoclonal antibody (CABT-RM237) are all available for sandwich ELISA. Recombinant Nipah Virus G Protein (DAGA-1004) and Recombinant Nipah Virus F Protein [His] (DAG-WT633) are also ready for research applications.
"Our NiV antigens are post-translationally modified and more closely resembling the native viral proteins, and these monoclonal antibodies can be used as a pair in sandwich ELISA with the rec. protein or in capture IgM assays. Our products are specific to NiV, no cross reaction with Dengue, Zika and Chikungunya envelope proteins." said Dr. Jessica Waldorf, chief scientific officer of R&D department of Creative Diagnostics.
If you want to know more details about NiV antigen and antibody products list or have any other questions about our research materials, please visit Creative Diagnostics at https://www.creative-diagnostics.com.
Creative Diagnostics
New York, USA
Contact Us
Tel: 1-631-624-4882 (USA)
44-161-818-6441 (Europe)
Fax: 1-631-938-8221
Email: info@creative-diagnostics.com
About Creative Diagnostics
Creative Diagnostics is a leading manufacturer and supplier of antibodies, viral antigens, innovative diagnostic components and critical assay reagents. It also provides contract biologic R&D and manufacturing services to the diagnostic manufacturers along with GMP biologics manufacturing for the biopharmaceutical market. It aims to provide a trusted source for all researchers' assay development and manufacturing needs.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Creative Diagnostics Introduces New Nipah Virus Antigens and Antibodies here
News-ID: 2610389 • Views: …
More Releases from Creative Diagnostics
Creative Diagnostics Launches New Anti-Small Molecule Label Antibodies to Facili …
Creative Diagnostics, a leading manufacturer and supplier of antibodies, antigens and assay kits, has recently announced a series of new Anti-Small Molecule Label Antibodies to facilitate the development of nucleic acid lateral flow immunoassay (NALFIA). These antibodies can specifically bind to small molecule labels and offer customers multiple choices, including Anti Digoxin monoclonal antibodies, Anti-Fluorescien monoclonal antibodies, and Anti-FAM polyclonal antibodies.
Traditional nucleic acid detection methods require trained operators and sophisticated…
Creative Diagnostics Introduces New ELISA Kits to Accelerate Autoimmunity Resear …
Creative Diagnostics, a leading manufacturer and supplier of antibodies, antigens and assay kits, has announced a series of new ELISA Kits to assist researchers in studing the mechanisms of autoimmunity, including those associated with anti-neotrophil, anti-nuclear, rheumatic diseases, endocrine autoantibodies, and the neurological system.
The immune system has very powerful effector mechanisms to destroy a wide range of pathogens. Early in the study of immunity, it was recognized that if these…
Creative Diagnostics Launches New Reagent Solutions for Herpesvirus Research
Creative Diagnostics, a leading manufacturer and supplier of antibodies, antigens and assay kits, has announced the launch of new reagent solutions for herpesvirus research, including a range of Human Herpesviruses Antibodies designed to help researchers better understand the structure of Herpesvirus entry and develop new treatments and prevention strategies.
The Herpesviridae are a large family of double-stranded DNA enveloped viruses that cause a variety of diseases. The nine human herpesviruses are…
Creative Diagnostics Launches Highly Specific Antibodies Against FXIIIa/F13A1 fo …
Creative Diagnostics, a leading manufacturer and supplier of antibodies, antigens, and assay kits, has launched a set of highly specific antibodies against FXIIIa/F13A1 for vascular diseases. These antibodies can be used in various scientific applications such as WB, ELISA, IHC, and IP to facilitate drug development research.
Coagulation Factor XIIIa (FXIIIa) is a plasma transglutaminase that catalyzes the final step of the coagulation process and plays an important role in hemostasis.…
More Releases for NiV
North America Non-Invasive Ventilation Masks Market is expected to reach US$ 985 …
The North America non-invasive ventilation masks market is expected to reach US$ 985.8 million by 2028 from US$ 671.1 million in 2021. The market is estimated to grow at a CAGR of 5.6% from 2021 to 2028.
NIV reduces the endotracheal intubation rate, length of hospital stays, complications of mechanical ventilation, and mortality for specific populations, particularly with COPDs. Recent clinical practice guidelines recommend NIV as first-line ventilatory support for…
Omnix Medical Advances Novel Anti-Infective Program into Clinical Development
- Entirely novel therapeutic principle to combat alarming worldwide rise of antimicrobial resistance (AMR)
JERUSALEM, Israel, March 16, 2022 -- Omnix Medical, a biopharmaceutical company developing next-generation anti-infectives for the treatment of life-threatening infections, today announced it received approval by Dutch authorities to initiate a Phase I clinical trial with its lead compound OMN6 in healthy volunteers. The trial will be conducted in Groningen, The Netherlands.
OMN6, the lead compound of Omnix,…
Sleep Non-invasive Ventilator (NIV) Market 2021: Global Size, Supply-Demand, Pro …
"Market Summary
A newly published report titled “(Sleep Non-invasive Ventilator (NIV) Market)” by QY Research throws light on the industry dynamics and current and future trends that play a key role in determining the business expansion. The report also highlights the key driving factors and restraints that are impacting the growth. For a comprehensive understanding, the professionals have reviewed the regulatory scenario, market entry strategies, best industry practices, pricing strategy, technology…
Medical Non-invasive Ventilator (NIV) Market to Witness Huge Growth by 2026| Key …
ReportsnReports.com the exclusive leading provider of market research reports published research report on "Global Medical Non-invasive Ventilator (NIV) Market Research Report 2020".
The Global Medical Non-invasive Ventilator (NIV) Market Report 2020 is a professional and in-depth study on the current state of the Medical Non-invasive Ventilator (NIV) Market.
This report focuses on Medical Non-invasive Ventilator (NIV) volume and value at global level, regional level and company level. From a global perspective, this…
Global 3D Printing Mask Market Size, Trends & Analysis - Forecasts To 2026
Global 3D Printing Mask Market Size, Trends & Analysis - Forecasts To 2026 By Component (Non-Invasive Ventilation mask, Filter, PEEP Valve), By Material (Alloy, Polymer, Ceramics, Biological Cell, Others), By End User (Hospitals, Medical Centers, Medical Institutes, Others), By Region (North America, Europe, Asia Pacific and Rest of the World); Vendor Landscape, End User Landscape and Company Market Share Analysis & Competitor Analysis
3D Printing Mask Market Insights
The global 3D printing…
Respiratory Protection Market Set to Grow with CAGR of 10.0% By 2026 With Leadin …
"Global Respiratory Protection Market 2020" and Upcoming Growth for 2027 from various Effect and factors about market environment, competitive landscape, historical and current data for forecast Growth with technological innovation, upcoming technologies and the technical progressive CAGR. Respiratory Protection is a professional and comprehensive report covering market parameters about the industry. The report pinpoints on the leading market competitors with explaining company profile depending on SWOT analysis to illustrate the…
